We have undertaken studies on bovine liver argininosuccinase (L-argininosuccinate arginine-lyase, EC 4.3.2.1) with the active site-directed reagent bromo[U-14C]mesaconic acid, an analogue of fumaric acid. Reactivity, measured by enzyme inactivation, followed pseudo-first-order kinetics, and the rate increased with reagent concentration. Argininosuccinate completely protected the enzyme against inactivation, but neither arginine nor fumarate was protective. A plot of the degree of inactivation as a function of alkyl groups incorporated was extrapolated to 4 mol per mol of enzyme, or 1 mol per active site. After large-scale alkylation of the enzyme (and digestion with trypsin), two "4C-labeled tryptic peptides were isolated. These were chemically sequenced by the Edman method. The amino acid sequences proved to be identical with regions of the deduced amino acid sequences of argininosuccinases from human and yeast sources [O'
In the forward direction a N-C bond is cleaved by 1-elimination, involving the abstraction by a nucleophile of a proton from C-3 in the succinate moiety, to form fumarate, and the donation of a proton to the amidino group of argininosuccinate, to form arginine (1) . Since the enzyme lacks a prosthetic group (2, 3) and the guanidino nitrogen is strongly basic, N-C bond cleavage must be promoted by an electrophilic displacement at N--C, proceeding through a symmetrical transition state (3) . Interest in the reaction mechanism of the enzyme has more recently focused on the acid-base requirements from which to deduce the number of proton acceptor and donor residues (4) . This kinetic analysis has led to reversible inactivation with diethylpyrocarbonate and the suggestion that a histidine residue and a carboxyl group, probably on another amino acid residue, may participate in the catalytic mechanism (4) .
We have pursued modification of argininosuccinase through the use of active site-directed agents. The oligomeric structure of the enzyme is tetrameric and the four subunits (each 50 kDa) are identical (5) . As shown by Rochovansky (6) , the enzyme has four binding sites for argininosuccinate, one per subunit; each binding site is presumably equivalent to one active site. In the present paper we describe studies in which the substrate analogue bromomesaconic acid was used as an active site-directed alkylating agent. These studies are a first step in the characterization of the active site region. The enzyme is subject to genetic mutation in humans more frequently than several other urea cycle enzymes. Clinical symptoms become evident neonatally. Knowledge of the critical amino acid residues involved in catalysis is important in characterizing the genetic lesions. The identification of active site residues is also valuable in the design of in vitro site-directed mutagenesis of the human enzyme. Materials. [U-_4C]Glutamate was purchased from New England Nuclear; acetonitrile, from Burdick and Jackson (Muskegon, MI); trifluoroacetic acid, standard amino acids, triethylamine, and phenylisothiocyanate, from Pierce.
MATERIALS AND METHODS
Preparation and Assay of Argininosuccinase. The enzyme was isolated from bovine liver according to the procedures published from this laboratory (5-7). The specific activity was 1430 ,mol of substrate cleaved per hr per mg of protein at 38°C (5) . Rates of argininosuccinate cleavage were followed at 23°C by a continuous assay, from the increase in absorbance at 240 nm as fumarate is formed (8) with a 3-hr gradient (0-60% eluant B at 1 ml/min) and was monitored at 220 nm. The peptides were collected manually and radioactivity was determined on small aliquots. Two or three peptides with significant 14C were located. The 14C-labeled peptides were isolated from the remaining mixture of tryptic peptides by repeated runs on a high-capacity column (4-fold larger) of the same kind. The two 14C-labeled peptides nos. 3129 and 3230 were each pooled, divided, lyophilized, and stored at -20'C. The final purification step made use of a Whatman analytical 5P-ODS-3 column with a small guard column and a gradient mixture resembling eluants A and B described above; homogeneity was assessed during numerous trials by recovery of cpm and peak symmetry. The injection volume (and load) was kept small (50-60 Al) to retain good resolution, as judged from the symmetry of the eluted peak; thus, six or seven repeated runs were necessary. One-tenth of the pool was used for measurement of cpm. Both fractions 3129 and 3230 were purified in this way. The two '4C-labeled bovine tryptic peptides were sequenced using an Applied Biosystems (Foster City, CA) gas-phase sequencer.
RESULTS AND DISCUSSION Preliminary active site studies with bromo analogues suggested that neither arginine nor succinate analogues were sufficiently reactive. The fact that fumarase has a substrate in common with argininosuccinase suggested that certain site-reactive alkylating agents found to be effective for fumarase-e.g., iodoacetate and bromocrotonate, described by Hill and his group (12, 13, 16) , and bromomesaconic acid, described by Laursen et al. (14, 15) -might be potential site-reactive alkylating reagents. These compounds were found to inactivate 50 AM solutions of argininosuccinase. For the series Na-bromoacetyl-L-arginine, DL-bromosuccinate, bromocrotonate, and bromomesaconate, each used at 10 mM, the rates of inactivation, expressed as the apparent first-order constant (k), were 0.00036, 0.0114, 0.078, and 0.162 hr-1, respectively. Full protection against inactivation was afforded by 2 mM argininosuccinate. The results clearly indicated that the enzyme was far more accessible to reactive analogues of fumaric acid than to analogues of moieties of argininosuccinate. Bromomesaconate proved to be the most reactive, for the rate of inactivation, 0.162 hr-1, could be appreciably increased by multiple additions of the reagent owing to its brief half-life (see Materials and Methods).
On the addition of bromomesaconic acid to argininosuccinase, the enzyme was inactivated at a rapid rate according to pseudo-first-order kinetics (Fig. 1) . Argininosuccinate (3 mM) fully protected against inactivation. As seen in Fig. 1 (Fig. 2) . The protection against inactivation afforded by argininosuccinate (Fig. 1) is highly specific, for neither arginine nor fumarate was found to exert protection. The stoichiometry of incorporation, and the fact that protection afforded by argininosuccinate is highly specific, suggests that the reagent is also specific for the active site. Isolation of 14C-Alkylated Tryptic Peptides. With these assurances, enzyme alkylations were carried out on a large scale under the conditions described in Materials and Methods. Several batches were subjected to the steps described, leading to resolution of the tryptic peptides by reversedphase HPLC. Close to 49 tryptic peptides were expected from the total number of arginine and lysine residues per subunit of argininosuccinase (17) . About 50-55 peaks emerged on elution and were numbered sequentially. Of these, only two or three contained significant radioactivity. After final purification, each of these contained -50 cpm (yield per 10 mg of enzyme). However, the number of peptide bonds judged by the absorbance at 220 nm differed by a factor of about 20. Only a few amino acids (tryptophan and histidine) have high absorbance in this region. The low specific radioactivity of the bromo[U-14C]mesaconic acid (25 cpm/nmol) and the small amount of purified material available limited further experiments to highly sensitive methods. Nevertheless, even when 200-pmol of peptide was acidhydrolyzed (6 M HCl, 24 hr, 110'C) and then analyzed by chromatography on a Waters Pico-Tag column, no unknown phenylthiocarbamoyl derivative (corresponding to the alkylated residue) or statistically significant radioactive peak was detected. To avoid acid hydrolysis, we turned to chemical sequencing.
Amino Acid Sequence of the "4C-Labeled Alkylated Peptides.
The two labeled peptides were each sequenced through 10 or 11 cycles by the Edman method, using a gas-phase sequencer (23) . The Table 1 the homology is higher: 83% for the 12 amino acid (residues 48-59).
The several amino acids in the human enzyme that precede and follow the alkylated peptide sequence 3129D indicate that this bovine peptide was indeed an intact tryptic peptide, since the chemical sequence began after arginine and terminated after lysine. The unknown phenylthiohydantoin derivative that appears in cycle 4 may therefore be construed to be an alkylated lysine residue and to account for the presence of radioactivity in peptide 3129D. The sample used for sequence analysis contained, at most, 8 cpm, in agreement with the phenylthiohydantoin peak area. That this lysine residue was blocked by alkylation is further supported by the fact that it was not susceptible to tryptic cleavage.
The second peptide fragment (3230D) containing radioactivity was also subjected to sequence analysis. The sample proved to contain two tryptic peptides, designated 3230D-a and 3230D-b in Table 1 . The successive yields of the phenylthiohydantoin derivatives of each pair of stable amino acids sequenced were plotted. The plots were linear with two distinct slopes, consistent with expectation for two separate tryptic peptides.
Peptide 3230D-a, run for 11 cycles, terminated in lysine and began after arginine, whereas the shorter peptide 3230D-b began after lysine and terminated with arginine. Through homology, then, the three isolated bovine sequences are established as being tryptic peptides. The sequence of peptide 3230D-a is identical to the human sequence at residues 12-24, except for one minor exception (threonine vs. alanine at position 16). The two are considered to be closely related. The third tryptic peptide sequence (3230D-b) is identical to the human sequence at residues 289-297. The similarities between the human and yeast sequence for 14 Bovine (peptide 3129D)* Gly-Leu-Glu-Xaa-Ala-Gly-Leu-Leu-Thr-Lys Human (residues 46-59)t Ser-Arg-Gly-Leu-Glu-Lys-Ala-Gly-Leu-Leu-Thr-Lys-Ala-Glu
Yeast (residues 46-59)t
Thr-Ala-Gly-Leu-Gln-Lys-Leu-Gly-Leu-Leu-Thr-Glu-Thr-Glu Bovine (peptide 323OD-a)* Phe-Val-Gly-Thr-Val-Asp-Pro-Ile-Met-Glu-Lys
Human (residues 11-24)t
Gly-Arg-Phe-Val-Gly-Ala-Val-Asp-Pro-Ile-Met-Glu-Lys-Phe Yeast (residues 11-24)t
Gly-Arg-Phe-Thr-Gly-Gly-Thr-Asp-Pro-Leu-Met-His-Leu-Tyr Bovine (peptide 323OD-b)* Asn-Pro-Asp-Ser-Leu-Glu-Leu-Ile-Arg
Human (residues 287-300)t
Lys-Lys-Asn-Pro-Asp-Ser-Leu-Glu-Leu-Ile-Arg-Ser-Lys-Ala
Yeast (residues 287-300)t
Lys-Lys-Asn-Ala-Asp-Ser-Leu-Glu-Leu-Leu-Arg-Gly-Lys-Ser *Sequence obtained by Edman degradation; numbers above bovine residues indicate degradation cycles. Xaa represents an unknown phenylthiohydantoin amino acid derivative observed in cycle 4 for peptide 3129D.
tSequence from the amino acid sequence deduced from cDNA for human argininosuccinase (18) . tSequence from the amino acid sequence deduced from the yeast (Saccharomyces cerevisiae) argininosuccinase gene ARG4 (19) .
71%, respectively, for residues 11-24 and residues 287-300. The sequence similarities among the three species serve to reinforce the sequence authenticity in the regions under study. Although alkylated peptide 3230D was isolated from the initial mixture of tryptic peptides on the basis of radioactivity, it markedly contrasted, as noted above, with peptide 3129D in that the ratio ofpeptide bonds (A220) to radioactivity was 20-fold greater for 3230D than for 3129D; consequently, the aliquot injected contained insufficient radioactivity to allow detection of an unknown phenylthiohydantoin derivative. However, the reactive methionine in peptide 3230D-a should be considered as a possibility. Other investigators have found methionine reactivity with other site-directed alkyl halides for fumarase (13) ; but in this case, the alkylation, and inactivation, may have been fractional.
Judging from the composition of peptide 3230D-b, its presence might be explained simply on the basis of copurification with peptide 3230D-a.
Evidence for Lysine in the Active Site. The complete similarity of the sequence of tryptic peptide 3129D to the sequences of the human and yeast enzymes is the strongest evidence that lysine is the modified amino acid residue in the active site region. In addition, the relationship of injected radioactivity to peak area (60-70%) speaks for lysine-51 being the site of a modification approaching stoichiometric proportions (cf. Figs. 1 and 2) . Earlier in our study on possible substrate binding sites of argininosuccinase, experiments were conducted by using pyridoxal phosphate as a probe. With a 4-fold excess of pyridoxal phosphate over enzyme active sites, the Schiffbase spectrum was obtained and absorbance at 425 nm increased to a maximum at 1 mM pyridoxal phosphate. Separate experiments in which pyridoxal phosphate was followed by NaBH4 reduction showed, under suitably controlled conditions, that inactivation of the enzyme was proportional to the number of pyridoxal phosphate groups bound; a value between one and two groups per active site was obtained. The use of pyridoxal phosphate as a probe (followed by stabilization by reduction) has frequently allowed identification an active site lysine (20) (21) (22) . Our preliminary findings with pyridoxal phosphate serve to reinforce the presence of lysine in the active site region.
In the absence of direct evidence it is difficult to affirm the mode of modification of the n-amino group. Alkylation of a lysine side chain of fumarase by reactive bromo derivatives was found in trace amounts in one of the reactions studied by Hill and his group (13) , and lysine was not found to be involved in the study of fumarase with bromomesaconic acid by Laursen et al. (14, 15 
